Trade Krystal Biotech, Inc. - KRYS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.33 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Krystal Biotech Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 103.8 |
Open* | 104.45 |
1-Year Change* | 38.05% |
Day's Range* | 102.89 - 105.08 |
52 wk Range | 69.81-132.68 |
Average Volume (10 days) | 376.62K |
Average Volume (3 months) | 6.54M |
Market Cap | 2.86B |
P/E Ratio | -100.00K |
Shares Outstanding | 28.21M |
Revenue | 8.56M |
EPS | -1.46 |
Dividend (Yield %) | N/A |
Beta | 0.83 |
Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 5, 2023 | 103.80 | 0.92 | 0.89% | 102.88 | 104.96 | 101.38 |
Dec 4, 2023 | 104.68 | -0.44 | -0.42% | 105.12 | 106.22 | 103.51 |
Dec 1, 2023 | 106.04 | 1.93 | 1.85% | 104.11 | 106.13 | 101.06 |
Nov 30, 2023 | 104.15 | 3.72 | 3.70% | 100.43 | 105.74 | 100.43 |
Nov 29, 2023 | 100.25 | 0.31 | 0.31% | 99.94 | 103.08 | 99.93 |
Nov 28, 2023 | 100.81 | 1.67 | 1.68% | 99.14 | 101.43 | 98.13 |
Nov 27, 2023 | 100.50 | -1.95 | -1.90% | 102.45 | 103.38 | 99.59 |
Nov 24, 2023 | 102.38 | 0.43 | 0.42% | 101.95 | 103.74 | 101.50 |
Nov 22, 2023 | 101.88 | 0.70 | 0.69% | 101.18 | 102.91 | 100.15 |
Nov 21, 2023 | 101.17 | -1.72 | -1.67% | 102.89 | 104.18 | 99.93 |
Nov 20, 2023 | 104.71 | -1.01 | -0.96% | 105.72 | 107.04 | 103.93 |
Nov 17, 2023 | 104.09 | 6.21 | 6.34% | 97.88 | 104.14 | 96.73 |
Nov 16, 2023 | 98.18 | -1.31 | -1.32% | 99.49 | 99.79 | 96.66 |
Nov 15, 2023 | 99.49 | -1.45 | -1.44% | 100.94 | 103.53 | 98.93 |
Nov 14, 2023 | 102.71 | 1.11 | 1.09% | 101.60 | 104.98 | 101.60 |
Nov 13, 2023 | 99.57 | 4.89 | 5.16% | 94.68 | 100.32 | 94.68 |
Nov 10, 2023 | 98.47 | 2.67 | 2.79% | 95.80 | 98.92 | 93.63 |
Nov 9, 2023 | 95.88 | -5.69 | -5.60% | 101.57 | 101.60 | 95.73 |
Nov 8, 2023 | 102.17 | -6.00 | -5.55% | 108.17 | 108.17 | 101.44 |
Nov 7, 2023 | 108.96 | 5.20 | 5.01% | 103.76 | 109.46 | 103.43 |
Krystal Biotech, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, February 26, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Krystal Biotech Inc Earnings Release Q4 2023 Krystal Biotech Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | |||||
Total Operating Expense | 145.196 | 68.275 | 32.999 | 22.081 | 11.916 |
Selling/General/Admin. Expenses, Total | 77.735 | 40.391 | 15.063 | 6.465 | 4.155 |
Research & Development | 42.461 | 27.884 | 17.936 | 15.616 | 7.761 |
Operating Income | -145.196 | -68.275 | -32.999 | -22.081 | -11.916 |
Interest Income (Expense), Net Non-Operating | 5.221 | -1.295 | 0.832 | 2.993 | 1.027 |
Net Income Before Taxes | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 |
Net Income After Taxes | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 |
Net Income Before Extra. Items | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 |
Net Income | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 |
Income Available to Common Excl. Extra. Items | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 |
Income Available to Common Incl. Extra. Items | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 |
Dilution Adjustment | |||||
Diluted Net Income | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 |
Diluted Weighted Average Shares | 25.4917 | 22.1968 | 18.7872 | 15.9011 | 11.2031 |
Diluted EPS Excluding Extraordinary Items | -5.491 | -3.13423 | -1.71218 | -1.20042 | -0.97196 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -4.51029 | -3.13423 | -1.71218 | -1.20042 | -0.97196 |
Total Extraordinary Items | 0 | ||||
Total Adjustments to Net Income | 0 | ||||
Unusual Expense (Income) | 25 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 38.048 | 48.823 | 34.771 | 31.451 | 28.753 |
Selling/General/Admin. Expenses, Total | 25.904 | 24.035 | 24.03 | 19.935 | 17.863 |
Research & Development | 12.144 | 12.288 | 10.741 | 11.516 | 10.89 |
Operating Income | -38.048 | -48.823 | -34.771 | -31.451 | -28.753 |
Interest Income (Expense), Net Non-Operating | 4.838 | 3.526 | 2.719 | 1.601 | 0.645 |
Net Income Before Taxes | -33.21 | -45.297 | -32.052 | -29.85 | -28.108 |
Net Income After Taxes | -33.21 | -45.297 | -32.052 | -29.85 | -28.108 |
Net Income Before Extra. Items | -33.21 | -45.297 | -32.052 | -29.85 | -28.108 |
Net Income | -33.21 | -45.297 | -32.052 | -29.85 | -28.108 |
Income Available to Common Excl. Extra. Items | -33.21 | -45.297 | -32.052 | -29.85 | -28.108 |
Income Available to Common Incl. Extra. Items | -33.21 | -45.297 | -32.052 | -29.85 | -28.108 |
Diluted Net Income | -33.21 | -45.297 | -32.052 | -29.85 | -28.108 |
Diluted Weighted Average Shares | 26.6569 | 25.7122 | 25.6826 | 25.6191 | 25.5452 |
Diluted EPS Excluding Extraordinary Items | -1.24583 | -1.76169 | -1.248 | -1.16515 | -1.10033 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.24583 | -1.27554 | -1.248 | -1.16515 | -1.10033 |
Unusual Expense (Income) | 0 | 12.5 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 383.779 | 442.267 | 275.058 | 195.88 | 112.65 |
Cash and Short Term Investments | 379.171 | 438.096 | 271.262 | 193.685 | 111.761 |
Cash & Equivalents | 161.9 | 341.246 | 268.269 | 187.514 | 103.67 |
Prepaid Expenses | 4.608 | 4.171 | 3.796 | 2.195 | 0.889 |
Other Current Assets, Total | |||||
Total Assets | 558.45 | 626.295 | 310.844 | 209.023 | 116.116 |
Property/Plant/Equipment, Total - Net | 169.726 | 119.583 | 34.174 | 11.184 | 3.014 |
Property/Plant/Equipment, Total - Gross | 176.519 | 123.797 | 36.542 | 12.034 | 3.18 |
Accumulated Depreciation, Total | -6.793 | -4.214 | -2.368 | -0.85 | -0.166 |
Total Current Liabilities | 28.847 | 25.736 | 15.452 | 3.327 | 2.596 |
Accounts Payable | 3.981 | 8.398 | 2.105 | 0.724 | 0.888 |
Accrued Expenses | 24.556 | 17.168 | 5.681 | 2.544 | 1.515 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Total Liabilities | 36.219 | 32.719 | 18.76 | 6.109 | 2.89 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Other Liabilities, Total | 7.372 | 6.983 | 3.308 | 2.782 | 0.294 |
Total Equity | 522.231 | 593.576 | 292.084 | 202.914 | 113.226 |
Redeemable Preferred Stock | 0 | 0 | |||
Common Stock | 0.00026 | 0.003 | 0.0002 | 0.00017 | 0 |
Additional Paid-In Capital | 803.718 | 734.523 | 363.292 | 241.951 | 133.183 |
Retained Earnings (Accumulated Deficit) | -280.759 | -140.787 | -71.214 | -39.047 | -19.959 |
Total Liabilities & Shareholders’ Equity | 558.45 | 626.295 | 310.844 | 209.023 | 116.116 |
Total Common Shares Outstanding | 25.7637 | 25.208 | 19.7142 | 17.3543 | 14.4289 |
Other Current Liabilities, Total | 0.31 | 0.17 | 7.666 | 0.059 | 0.193 |
Short Term Investments | 217.271 | 96.85 | 2.993 | 6.171 | 8.091 |
Other Long Term Assets, Total | 0.324 | 0.074 | 1.612 | 1.462 | 0.452 |
Other Equity, Total | -0.72826 | -0.163 | 0.0058 | 0.00983 | 0.002 |
Long Term Investments | 4.621 | 64.371 | 0 | 0.497 | |
Preferred Stock - Non Redeemable, Net | 0 | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 582.128 | 484.004 | 355.429 | 383.779 | 397.578 |
Cash and Short Term Investments | 562.069 | 477.517 | 350.387 | 379.171 | 394.42 |
Cash & Equivalents | 373.241 | 275.875 | 140.745 | 161.9 | 186.409 |
Short Term Investments | 188.828 | 201.642 | 209.642 | 217.271 | 208.011 |
Prepaid Expenses | 5.465 | 6.487 | 5.042 | 4.608 | 3.158 |
Total Assets | 790.35 | 684.026 | 531.847 | 558.45 | 576.379 |
Property/Plant/Equipment, Total - Net | 171.389 | 171.327 | 170.887 | 169.726 | 166.039 |
Property/Plant/Equipment, Total - Gross | 182.128 | 180.471 | 178.773 | 176.519 | 171.84 |
Accumulated Depreciation, Total | -10.739 | -9.144 | -7.886 | -6.793 | -5.801 |
Other Long Term Assets, Total | 0.285 | 0.285 | 0.402 | 0.324 | 0.205 |
Total Current Liabilities | 27.583 | 23.898 | 35.076 | 28.847 | 28.032 |
Accounts Payable | 4.34 | 4.446 | 4.109 | 3.981 | 5.761 |
Accrued Expenses | 20.776 | 18.778 | 30.595 | 24.556 | 21.681 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.467 | 0.674 | 0.372 | 0.31 | 0.59 |
Total Liabilities | 34.402 | 30.912 | 42.281 | 36.219 | 35.607 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 6.819 | 7.014 | 7.205 | 7.372 | 7.575 |
Total Equity | 755.948 | 653.114 | 489.566 | 522.231 | 540.772 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Common Stock | 0.00028 | 0.00028 | 0.00026 | 0.00026 | 0.00026 |
Additional Paid-In Capital | 1034.85 | 1012.62 | 815.776 | 803.718 | 790.954 |
Retained Earnings (Accumulated Deficit) | -278.519 | -359.266 | -326.056 | -280.759 | -248.707 |
Other Equity, Total | -0.38228 | -0.23628 | -0.15426 | -0.72826 | -1.47526 |
Total Liabilities & Shareholders’ Equity | 790.35 | 684.026 | 531.847 | 558.45 | 576.379 |
Total Common Shares Outstanding | 28.1947 | 27.9749 | 25.7962 | 25.7637 | 25.7097 |
Long Term Investments | 36.548 | 28.41 | 5.129 | 4.621 | 12.557 |
Total Receivables, Net | 9.316 | ||||
Accounts Receivable - Trade, Net | 9.316 | ||||
Total Inventory | 5.278 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 |
Cash From Operating Activities | -100.569 | -47.938 | -26.083 | -18.69 | -9.445 |
Cash From Operating Activities | 4.055 | 2.769 | 1.851 | 1.09 | 0.141 |
Non-Cash Items | 32.54 | 16.811 | 3.305 | 1.306 | 0.792 |
Cash Taxes Paid | |||||
Cash Interest Paid | |||||
Changes in Working Capital | 2.811 | 2.052 | 0.928 | -1.998 | 0.511 |
Cash From Investing Activities | -114.083 | -226.77 | -11.181 | -4.991 | -10.323 |
Capital Expenditures | -52.979 | -68.336 | -14.843 | -6.399 | -2.234 |
Cash From Financing Activities | 35.347 | 347.685 | 118.019 | 107.525 | 73.847 |
Issuance (Retirement) of Stock, Net | 35.996 | 355.645 | 118.019 | 107.525 | 73.847 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Net Change in Cash | -179.346 | 72.977 | 80.755 | 83.844 | 54.079 |
Other Investing Cash Flow Items, Total | -61.104 | -158.434 | 3.662 | 1.408 | -8.089 |
Financing Cash Flow Items | -0.649 | -7.96 | |||
Foreign Exchange Effects | -0.041 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -45.297 | -139.975 | -107.923 | -78.073 | -49.965 |
Cash From Operating Activities | -26.156 | -100.569 | -78.24 | -58.552 | -15.493 |
Cash From Operating Activities | 0.705 | 4.055 | 2.966 | 1.991 | 1.015 |
Non-Cash Items | 9.832 | 32.54 | 23.476 | 14.453 | 6.295 |
Changes in Working Capital | 8.604 | 2.811 | 3.241 | 3.077 | 27.162 |
Cash From Investing Activities | 3.563 | -114.083 | -108.875 | -94.132 | -55.908 |
Capital Expenditures | -5.381 | -52.979 | -47.762 | -33.706 | -17.191 |
Other Investing Cash Flow Items, Total | 8.944 | -61.104 | -61.113 | -60.426 | -38.717 |
Cash From Financing Activities | 1.474 | 35.347 | 32.278 | 30.158 | -0.542 |
Financing Cash Flow Items | -0.749 | -0.649 | -0.649 | -0.649 | -0.649 |
Issuance (Retirement) of Stock, Net | 2.223 | 35.996 | 32.927 | 30.807 | 0.107 |
Net Change in Cash | -21.155 | -179.346 | -154.837 | -122.526 | -71.943 |
Foreign Exchange Effects | -0.036 | -0.041 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Redmile Group, LLC | Investment Advisor/Hedge Fund | 9.1686 | 2566661 | 653381 | 2023-06-30 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 9.1477 | 2560811 | 810811 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 8.9378 | 2502059 | -111213 | 2023-06-30 | LOW |
Krishnan (Krish S) | Individual Investor | 6.106 | 1709338 | -25000 | 2023-09-11 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.0818 | 1702554 | 503610 | 2023-06-30 | LOW |
Krishnan (Suma M) | Individual Investor | 6.0341 | 1689206 | -25000 | 2023-09-11 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.1634 | 1445463 | -5791 | 2023-06-30 | LOW |
Frazier Healthcare Partners | Venture Capital | 3.5374 | 990260 | 44853 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.2281 | 903691 | -122704 | 2023-06-30 | LOW |
Lord, Abbett & Co. LLC | Investment Advisor | 3.0101 | 842648 | -118594 | 2023-06-30 | MED |
Point72 Asset Management, L.P. | Hedge Fund | 1.9978 | 559261 | 56861 | 2023-06-30 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.7382 | 486597 | 24507 | 2023-06-30 | LOW |
Credit Suisse Funds AG | Investment Advisor/Hedge Fund | 1.6604 | 464818 | -168001 | 2023-06-30 | LOW |
Hood River Capital Management LLC | Investment Advisor | 1.6163 | 452456 | 5063 | 2023-06-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.587 | 444260 | 13689 | 2023-06-30 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.534 | 429428 | -202965 | 2023-06-30 | LOW |
Nicholas Investment Partners, L.P. | Investment Advisor/Hedge Fund | 1.3394 | 374951 | 233 | 2023-06-30 | MED |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.2491 | 349669 | -62413 | 2023-06-30 | MED |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.1221 | 314110 | 300652 | 2023-06-30 | LOW |
SEB Investment Management AB | Investment Advisor | 1.0211 | 285860 | -158 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Krystal Biotech, Inc. Company profile
About Krystal Biotech Inc
Krystal Biotech, Inc. is a clinical stage biotechnology company focused on redosable gene delivery for the treatment of serious rare diseases. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Krystal Biotech Inc revenues was not reported. Net loss increased from $32.2M to $69.6M. Higher net loss reflects General and Administrative - Balancing increase from $12.8M to $30.2M (expense), Stock-based Compensation in SGA increase from $2.3M to $10.2M (expense), Research and Development - Balancing increase of 44% to $24.5M (expense).
Industry: | Bio Therapeutic Drugs |
2100 Wharton St Ste 701
PITTSBURGH
PENNSYLVANIA 15203
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com